申请人:Astellas Pharma Inc.
公开号:US20170233402A1
公开(公告)日:2017-08-17
Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
本文披露了一种新型四氢异喹啉衍生物化合物,可用作药物组合物的活性成分,特别是用于预防或治疗对调节骨骼肌肌丝收缩性反应的疾病或病况的药物组合物。例如,通过调节快速骨骼肌肌丝的肌钙蛋白复合物中的一个或多个,如快速骨骼肌肌肉球蛋白、肌动蛋白、肌动蛋白、肌钙蛋白C、肌钙蛋白I和肌钙蛋白T,以及其片段和同分异构体,可以实现这一目标。因此,四氢异喹啉衍生物化合物可用作预防或治疗以下疾病:1)神经肌肉疾病,2)自主肌肉疾病,3)中枢神经系统疾病,其中肌无力、萎缩和疲劳是突出症状,4)源自全身性疾病的肌肉症状,以及5)盆底和尿道/肛门括约肌功能障碍。